1. Nair JK, Willoughby JLS, Chan A, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136(49):16958–61.
2. German CA, Shapiro MD. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9. BioDrugs. 2020;34(1):1–9.
3. European Medicines Agency. Leqvio 284 mg solution for injection in pre-filled syringe: summary of product characteristics. 2021. http://www.ema.europa.eu/. Accessed 25 Jan 2021.
4. European Medicines Agency. Leqvio (inclisiran): an overview of Leqvio and why it is authorised in the EU. 2021. http://www.ema.europa.eu/. Accessed 25 Jan 2021.
5. Novartis. Novartis receives EU approval for Leqvio® (inclisiran), a first-in-class siRNA to lower cholesterol with two doses a year [media release]. 11 Dec 2020. http://www.novartis.com/.